1 / 29

EGFR Inhibitors in Advanced NSCLC

Lung Cancer - Background. Leading cause of cancer-related mortality 2007 statistics: 210k new cases 160k deaths~87%: non-small cell lung cancer (NSCLC)*Median survival ~10 mos. (advanced stage). *Govindan R, Page N, Morgensztern D et al., J Clin Oncol 2006; 24:4539-44.. Lung Cancer - Epidemiolo

gin
Download Presentation

EGFR Inhibitors in Advanced NSCLC

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. EGFR Inhibitors in Advanced NSCLC Hematology Grand Rounds Tom Fong, M.D. January 4, 2008

    2. Lung Cancer - Background Leading cause of cancer-related mortality 2007 statistics: 210k new cases 160k deaths ~87%: non-small cell lung cancer (NSCLC)* Median survival ~10 mos. (advanced stage)

More Related